Sanofi insulin insulin injection glycodes was approved by the FDA

recently, Sanofi announced that its insulin glaucin injection, Toujeo, has FDA approval to treat children with type 1 diabetes aged 6 years and older. Previously, sugar can only be used to treat adults over the age of 18 with diabetes.Glycodes is a long-acting insulin glaucin injection with a size of 300U/mL. In February 2015, the drug was approved by the FDA for the treatment of type 1 diabetes in adults. Sugar's main competitor is Novo Nordisk's ultra-long-acting treatment, Tigrudek, which is marketed as Tresiba. In 2018, sugar sales were $840 million, while Tresiba sales were $1.22 billion.Sanofi conducted the first randomized controlled trial, the EDITION JUNIOR clinical trial, on patients with type 1 diabetes between the ages of 6 and 17 to compare the clinical efficacy of Syndergam and insulin gla-gla-100 in this patient group. The study evaluated the efficacy of 463 children and adolescents with type 1 diabetes over a one-year period.In early November 2019, Sanofi published data on the CLINICAL study of ITION JUNIOR at the 45th Annual Meeting of the International Association for Childhood and Adolescent Diabetes (ISPAD). Trials showed that the average blood sugar level decreased significantly over a six-month period after patients were treated with glycodes and Gla-100, respectively, and that the risk of low blood sugar events was similar. In fact, the risk of glycosterone therapy causing severe hypoglycemia and hyperglycemia is numerically lower. Based on these data, the European Medicines Agency (EMA) Committee on Medical Products for People (CHMP) is considering expanding saccharine adaptation for the treatment of children and adolescents with type 1 diabetes.Founded in 1973 and headquartered in Paris, France, Sanofi (NYSE: SNY) is a leading pharmaceutical company in the world. The company specializes in the development, manufacture and marketing of innovative drugs to provide innovative solutions for healthcare professionals and patients. Sanofi's business areas include diabetes solutions, vaccines, innovative drugs, consumer health care and other emerging markets, and its products can be used to treat blood clots, cardiovascular diseases, diabetes, central nervous system diseases, oncology and medical diseases. Today, the company operates in more than 100 countries and regions around the world.Thomas Danne, head of the Department of General Paediatrics and Diabetes at Children's Hospital, said: "People with type 1 diabetes need to be aware of blood sugar levels at all times, and the disease poses a huge challenge to medicine. The results of clinical trials at Sugar Des are encouraging and demonstrate the drug's potential for treatment in children with type 1 diabetes.50 to 80 per cent of people with type 1 diabetes worldwide need better treatment options to help them lower their average blood sugar levels to the normal range, says Dietmar Berger, head of global development at . By studying the pathogenesis of diabetes in children and adolescents, we hope to provide them with personalized treatment plans to help them better manage their disease. The
(arterial network)